Rama Krishna Nimmakayala
Overview
Explore the profile of Rama Krishna Nimmakayala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
680
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer
Muniyan S, Vengoji R, Nimmakayala R, Seshacharyulu P, Perumalsamy B, Alsafwani Z, et al.
Cancer Lett
. 2024 Nov;
609():217355.
PMID: 39603380
Advanced prostate cancer (PCa) remains a significant clinical challenge, and docetaxel plays a significant role in disease management. Despite the efficacy of docetaxel as a first-line chemotherapy, resistance often develops....
2.
Ogunleye A, Gayen N, Rauth S, Marimuthu S, Nimmakayala R, Alsafwani Z, et al.
Cancer Metab
. 2024 Sep;
12(1):26.
PMID: 39242538
Background: PAF1/PD2 deregulation contributes to tumorigenesis, drug resistance, and cancer stem cell maintenance in Pancreatic Cancer (PC). Recent studies demonstrate that metabolic reprogramming plays a role in PC progression, but...
3.
Parte S, Pothuraju R, Kumavath R, Bhatia R, Nimmakayala R, Gautam S
Front Endocrinol (Lausanne)
. 2024 Jun;
15:1390877.
PMID: 38841308
No abstract available.
4.
Parte S, Kaur A, Nimmakayala R, Ogunleye A, Chirravuri R, Vengoji R, et al.
Gastroenterology
. 2023 Dec;
166(5):842-858.e5.
PMID: 38154529
Background & Aims: Pancreatic ductal adenocarcinoma (PDAC) is characterized by desmoplastic stroma surrounding most tumors. Activated stromal fibroblasts, namely cancer-associated fibroblasts (CAFs), play a major role in PDAC progression. We...
5.
Ogunleye A, Nimmakayala R, Batra S, Ponnusamy M
Stem Cells
. 2023 Mar;
41(5):417-430.
PMID: 36869789
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive diseases with a poor 5-year survival rate. PDAC cells rely on various metabolic pathways to fuel their unlimited proliferation and...
6.
Chirravuri-Venkata R, Dam V, Nimmakayala R, Alsafwani Z, Bhyravbhatla N, Lakshmanan I, et al.
Front Oncol
. 2023 Feb;
13:1073820.
PMID: 36816942
MUC16/CA125 is one of the few oldest cancer biomarkers still used in current clinical practice. As mesothelium is an abundant source of MUC16 and a major contributor to stromal heterogeneity...
7.
Rauth S, Ganguly K, Atri P, Parte S, Nimmakayala R, Varadharaj V, et al.
Cell Rep
. 2023 Jan;
42(2):112043.
PMID: 36709426
Cisplatin- and gemcitabine-based chemotherapeutics represent a mainstay of cancer therapy for most solid tumors; however, resistance limits their curative potential. Here, we identify RNA polymerase II-associated factor 1 (PAF1) as...
8.
Nallasamy P, Nimmakayala R, Parte S, Are A, Batra S, Ponnusamy M
Mol Cancer
. 2022 Dec;
21(1):225.
PMID: 36550571
Cancer divergence has many facets other than being considered a genetic term. It is a tremendous challenge to understand the metastasis and therapy response in cancer biology; however, it postulates...
9.
Raut P, Nimmakayala R, Batra S, Ponnusamy M
Biochim Biophys Acta Rev Cancer
. 2022 Dec;
1878(1):188851.
PMID: 36535512
Intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs) are all considered "Pancreatic cystic neoplasms (PCNs)" and show a varying risk of developing into pancreatic ductal adenocarcinoma (PDAC). These...
10.
Zhang C, Atri P, Nallasamy P, Parte S, Rauth S, Nimmakayala R, et al.
Cancer Lett
. 2022 Oct;
551:215922.
PMID: 36285687
Mucin MUC4 is an aberrantly expressed oncogene in pancreatic ductal adenocarcinoma (PDAC), yet no pharmacological inhibitors have been identified to target MUC4. Here, we adapted an in silico screening method...